Ask a question about this product
Interleukin-33/Receptor Targeted Antibodies – Target Pipeline List 12/2018
Target: Interleukin-33; IL-33; Suppression of Tumorigenicity 2 (ST2) receptor; interleukin-1 receptor-like 1 (IL1RL1)
This report provides an overview of antibodies targeting interleukin-33 (IL-33) or its receptor ST2 (IL1RL1) in clinical development for treatment of atopic diseases.
Interleukin-33 (IL-33) is an IL-1 family member, which exhibits both pro- and anti-inflammatory properties solely based on the type of the disease itself. Generally, IL-33 is expressed by both endothelial and epithelial cells and mediates its function based on the interaction with various receptors, mainly with the receptor Suppression of Tumorigenicity 2 (ST2) variants. IL-33 is a potent inducer for the Th2 immune response.
IL-33 initiates its signalling pathway by binding to the ST2 receptor, or also known as IL-1R4, with variants which are comprised of ST2L, sST2, ST2V, and ST2LV. Apart from ST2, the interaction of IL-33 with a single immunoglobulin IL-1R-related molecule (SIGIRR) has been documented as well. With exception from other IL-1 family members, IL-33 is primarily involved in the Th2 immune response induction.
Multiple studies have indicated IL-33 as a central mediator of atopic diseases, including atopic dermatitis, food allergies and asthma. IL-33 directly mediates release of disease-associated downstream cytokines, which recruit pro-inflammatory cells that mediate atopic disease.
La Merie Publishing offers a low-cost product service providing information about active R&D projects for a given target in the format of Word tables.
The Word document with the Table is delivered by e-mail within 24 hours after receipt of the confirmed order. Usually, delivery time is less than one hour if ordered during European business hours.
The Target Pipeline List in the Word table contains information about:
File: ID no. in proprietary database
Drug name: trade name, INN, drug code(s), trivial name
Target/MoA: mechanism of action
Class of compound: description of type of molecule, formulation, way and mode of administration, application device
Company: originator of molecule and licensee(s) with territories
Category: treatment modalities, i.e. antibody, protein, peptide, RNA, DNA, cells, vaccine, small molecule
Indication: medical indication evaluated in preclinical or clinical study, combination regimens
R&D Phase: from research to market with reference to indication/study
Message: last verified information about project with source and date of information and hyperlink leading to source of information
Information about R&D projects is identified and retrieved from company publications including, but not limited to, press releases, presentations, website disclosures, SEC publications, regulatory documents, scientific abstracts and full papers, patent applications. Furthermore, public and proprietary databases are used including national and regional clinical trial databases, PubMed.